Characteristic	Garber 2006	Goldberg 2005	Hällsten 2002	Hanefeld 2007	Jung 2005
	I1: rosiglitazone 4 mg + metformin 2000 C1: glibenclamide 5 mg +metformin 1000 mg	I1: rosiglitazone 8 mg + diet C1: pioglitazone 45 mg+diet	I1: rosiglitazone 8 mg C1: metformin 2 g C2: placebo	I1: rosiglitazone (2 mg bid) + placebo I2: rosiglitazone (4 mg bid) + placebo C1: glibenclamide up to 15 mg + placebo	I1: rosiglitazone 4 mg+ glimepiride 4mg C1: metformin 1000 mg + glimepiride 4mg
[n] of participants who died	?	I1: 2 C1: 1	I1:0 C2:0 C1:0	I1: 0 I2: 0 C1: 0	?
[%] adverse events	I1: 63 (98/155) C1: 68 (108/160)	?	?	I1: 75.0 (150/200) I2: 75.4 (144/191) C1: 69.6 (144/207)	?
[%] serious adverse events	I1: 6 (9/155) C1: 4 (7/159)	?	?	?	?
[%] drop‐outs due to adverse events	I1: 4.4 (7/158) C1: 10 (16/160)	I1: 2.7 (10/366) C1: 2.7 (10/369)	I1:0 C2:0 C1:0	I1: 6 I2: 4.7 C1: 6.3	I1:? C1: 3.3 (1/30)
[%] oedema	?	?	?	I1: 3.5 (7/200) I2: 8.9 (17/191) C1: 1.9 (4/207)	?
haemoglobin [g/dl]	?	?	?	I1: ‐0.48 I2: ‐0.98 C1: 0	?
body weight [kg]	I1: +1.4 C1: +3	I1: 1.6 C1: 2.0	I1: + 0.6 C1: ‐ 2.0 C2: + 0.1	I1: 1.75 I2: 2.95 C1: 1.9	?
body mass index (BMI) [kg/m2]	?	?	?	?	?
[%] hypoglycaemic episodes	I1: 26 (41/155) C1: 73 (116/159)	?	?	I1: 0.5 (1/200) I2: 1.6 (3/191) C1: 12.1 (25/207)	?
[%] severe hypoglycaemic episodes	?	?	?	I1: I2: C1: 0.01	?
Notes	elevated levels of ALT ( > 3x pretreatment levels and > upper normal limit): I1: 2 patients C1: 3 patients	I1 + C1: no significant differences observed for: ‐ liver functions tests ‐ haemoglobin ans haematocrit ‐ hypoglycemic episodes ‐ adverse events (oedema, congestive heart failure)	body weight change data calculated	two hypoglycaemic events were severe and one required hospitalization; unclear in which medication group these events happened	./.
Footnotes ? = unclear; I = intervention; C = control; AE = adverse event; ALT = alanine aminotransferase